TABLE 1.
L3 treatment | No. of L3 that did not penetrate skin/total no. of L3 (%)
|
P value | ||
---|---|---|---|---|
Trial 1 | Trial 2 | Trial 3 | ||
Prevaccination serum | 2/40 (5) | 4/40 (10) | ||
Anti-MTP-1 serum | 30/40 (75) | 28/40 (70) | 0.024 | |
Phosphate-buffered saline | 0/300 (0) | 20/300 (7) | 0/300 (0) | |
EDTA (10 mM) | 180/300 (60) | 150/300 (50) | 130/300 (43) | 0.006 |
1,10-Phenanthroline (10 μM) | 130/300 (43) | 120/300 (40) | 140/300 (47) | 0.005 |
1,10-Phenanthroline (100 μM) | 170/300 (57) | 170/300 (57) | 200/300 (67) | 0.003 |
Each experiment was conducted two (sera) or three (chemical inhibitors) times, and the mean number of L3 that did not penetrate skin from three separate experiments per trial is presented.